Why SCYNEXIS, Inc. Is Making A Run

Scynexis shares made a handy gain early on Thursday after the company announced the results from a couple of its mid-stage trials. Specifically, the company evaluated two Phase 2 studies of SCY-078 and the results were very favorable. At the same time, Scynexis closed its $15 million term loan with Solar Capital Ltd. (NASDAQ: SLRC).

In the first study, treatment with oral SCY-078 in patients with vulvovaginal candidiasis (VVC), resulted in significantly better clinical cure rates and fewer recurrences of VVC at the four-month follow-up when compared to the standard of care (oral fluconazole).

Back to news